GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Mitesco Inc (OTCPK:MITI) » Definitions » Sloan Ratio %

Mitesco (Mitesco) Sloan Ratio % : 0.00% (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Mitesco Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Mitesco's Sloan Ratio for the quarter that ended in Mar. 2024 was 0.00%.

As of Mar. 2024, Mitesco has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Mitesco Sloan Ratio % Historical Data

The historical data trend for Mitesco's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mitesco Sloan Ratio % Chart

Mitesco Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3,062.38 - -9.38 -626.94 -

Mitesco Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Mitesco's Sloan Ratio %

For the Health Information Services subindustry, Mitesco's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mitesco's Sloan Ratio % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Mitesco's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Mitesco's Sloan Ratio % falls into.



Mitesco Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Mitesco's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2023 )-Cash Flow from Operations (A: Dec. 2023 )
-Cash Flow from Investing (A: Dec. 2023 ))/Total Assets (A: Dec. 2023 )
=(-13.332--0.76
-0)/0.003
=-419,066.67%

Mitesco's Sloan Ratio for the quarter that ended in Mar. 2024 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Mar. 2024 )
=(-7.671--0.879
-0)/0.056
=-12,128.57%

Mitesco's Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was -7.544 (Jun. 2023 ) + -1.552 (Sep. 2023 ) + 1.378 (Dec. 2023 ) + 0.047 (Mar. 2024 ) = $-7.67 Mil.
Mitesco's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 was -0.483 (Jun. 2023 ) + -0.328 (Sep. 2023 ) + 0.086 (Dec. 2023 ) + -0.154 (Mar. 2024 ) = $-0.88 Mil.
Mitesco's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 was 0 (Jun. 2023 ) + 0 (Sep. 2023 ) + 0 (Dec. 2023 ) + 0 (Mar. 2024 ) = $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mitesco  (OTCPK:MITI) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Mar. 2024, Mitesco has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Mitesco Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Mitesco's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Mitesco (Mitesco) Business Description

Traded in Other Exchanges
N/A
Address
18202 Minnetonka Boulevard, Suite 100, Deephaven, MN, USA, 55391
Mitesco Inc is a development stage company who acquires and implements technologies and services to improve the quality of care, reduce cost, and enhance consumer convenience. It is focused on developing a portfolio of companies that provide healthcare technology solutions and the team is adept at deal structures supportive of long term organizational value.
Executives
Lonnie Allen Plunk director 3525 PIEDMONT RD., NE, BUILDING 6, SUITE 700, ATLANTA GA 30305
Lawrence M. Diamond director 7535 EAST HAMPDEN AVENUE, SUITE 400, DENVER CO 80231
Phillip J Keller officer: Chief Financial Officer 2323 RING ROAD, ELIZABETHTOWN KY 42701
Sheila Schweitzer director 1200 CAROLINA CIRCLE, VERO BEACH FL 62962
Ingrid Jenny Lindstrom officer: Chief Legal Officer 1100 WILLS PLACE, GOLDEN VALLEY MN 55422
Juan Carlos Iturregui director 5606 ALBIA RD., BETHESDA MD 20816
Faraz Naqvi director 3001 HEARTHSTONE DRIVE, FORT COLLINS CO 80528
Thomas Brodmerkel director 7535 EAST HAMPDEN AVENUE, STE. 400, DENVER CO 80231
Julie R. Smith director 7535 EAST HAMPDEN AVENUE, SUITE 400, DENVER CO 80231
Ron Riewold officer: CHAIRMAN 37 NORTH ORANGE AVE, STE 500, ORLANDO FL 32801
Douglas Cole director C/O AMERICAN BATTERY METALS CORP, 930 TAHOE BLVD, STE 802-16, INCLINE VILLAGE NV 89451
James Philip Crone director, officer: Pres, Interim CFO, Sec, Dir 1355 PEACHTREE STREET, SUITE 1150, ATLANTA GA 30309
Morton James E Iii officer: President 549 VIKINGS LANE, ATLANTIC BEACH FL 32233
Deluca Louis George Jr officer: C.O.O. 194 EDWARDS DR, MABLETON GA 30126
Thomas W. Burnell officer: President and CEO 1355 PEACHTREE STREET, SUITE 1150, ATLANTA GA 30309